Therapeutic vaccine against cancer of the kidney is preparing to enter the market
One of the most common types of kidney cancer – carcinoma. If a patient with this diagnosis begin to form metastases, his chances of survival are greatly reduced, said "Remedium". At this stage, radiotherapy, chemotherapy and immunotherapy may no longer work.
Employees Immatics Biotechnologies GmbH figured out how to solve this problem. After some hard work they are presented to the first vaccine for the treatment of kidney cancer – IMA901. It includes ten proteins emitted carcinoma during growth.
Administration of the vaccine gave a strong immune response – are beginning to produce antibodies against cancer and activated leukocytes. At the moment, successfully conducted two stages of clinical trials.
According to the scientists, they were able to identify biomarkers, which can predict the effectiveness of a IMA901 individual. For example, the availability of apoprotein A-I and CC chemokine ligand 17 have a better immune response and increase survival.
Now under final stage of vaccine trials. If all goes well, the tool will soon arrive in the hands of doctors.